The first artificial heart approved for marketing, for China's medical industry, has a lot of impact, is a major breakthrough in China's medical industry, means that China's medical industry to the front end of the world, you can continue to innovate and develop, bring more resources to drive the development of the surrounding industry, if the price is reasonable, then this project will bring hope to more families of doctors and patients to see the doctor's The pressure will also reduce a lot, the future of medical care will be more scientific, pro-people.
After six years of collaborative research and development and clinical trials, the country's first artificial heart product was finally approved for marketing. on September 10, the Municipal Commission of Economy and Information Technology and the Municipal Drug Administration held a press conference to say that the implantable left ventricular assist system EVAHEART Ⅰ (hereinafter referred to as the Yongrenxin Artificial Heart) was officially approved for registration and marketing by the State Drug Administration. State Drug Administration registration and listing approval, and this is the first domestic approved artificial heart products,More importantly, the selling price after listing will be cheaper than similar products abroad by about 30%, which is what all the nationals want to see, are very happy.
After six years of collaborative research and development and clinical trials, the country's first artificial heart product has finally been approved for the market. on September 10, the Municipal Commission of Economy and Information Technology and Municipal Bureau of Pharmaceutical Supervision held a press conference to say that the implantable left ventricular assist system EVAHEART Ⅰ (hereinafter referred to as Yongren heart artificial heart) was officially approved by the State Drug Administration registration and listing, and this is the first domestic approved artificial heart products,More importantly, the selling price after the listing will be cheaper than similar products abroad by about 30%, which is what all the nationals would like to see, are very happy.
But the artificial heart was developed by a number of Japanese research institutes after more than 50 years of basic research and more than 20 years of joint design. It has been approved for sale in Japan and Europe, and has been granted an exemption from U.S. clinical trials (IDE), and more than 200 implantations have been completed. This device has the physical characteristics of "low rotational speed, high flow rate, easy to generate physiological pulsatile blood flow", and excellent biocompatibility, which can significantly reduce the risk of common complications after artificial heart implantation, for the time being, the maximum survival time of patients to be implanted with this device can be more than 10 years after the operation.
This innovative development has helped the economy, research, and staff of China's healthcare industry, and has increased the self-confidence of healthcare professionals, as well as the medical pool of talent.